Request Sample
Request discount

Radiopharmaceuticals Market Size, Share & Forecast (2026 - 2036)Size, Share & Growth Trends (2026 - 2036), By Product Type (Diagnostic Radiopharmaceuticals, PET [Fluorine-18, Gallium-68, Rubidium-82, Carbon-11], SPECT [Technetium-99m, Iodine-123, Thallium-201, Xenon-133], Therapeutic Radiopharmaceuticals [Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Samarium-153; Alpha Emitters: Radium-223, Actinium-225; Brachytherapy Isotopes: Cesium-131, Iridium-192]), By Application, End User, Technology & Region Analysis, 2026-2036

Request Sample
Request Discount
Enquiry before buying
Need Customization

Radiopharmaceuticals Market Overview

The global radiopharmaceuticals market represents a critical segment of the healthcare and nuclear medicine industry, encompassing radioactive compounds used for diagnostic imaging and targeted therapeutic applications. These products are essential in modern clinical practice for disease detection, organ function assessment, treatment planning, and precision-based care, particularly in oncology, cardiology, neurology, and other specialized medical fields. Radiopharmaceuticals are commonly utilized in PET and SPECT imaging systems, enabling healthcare professionals to diagnose and monitor diseases with high clinical accuracy.

In 2026, the global radiopharmaceuticals market is valued at approximately USD 7.82 billion and is projected to reach USD 13.78 billion by 2036, registering a compound annual growth rate (CAGR) of 5.48% over the forecast period. These estimates are based on Quintile Reports primary research, cross-validated against data from industry associations, nuclear medicine institutional databases, and publicly available manufacturer disclosures.

Unlike aggregated secondary compilations, this report incorporates direct primary research conducted with radiopharmaceutical manufacturers, nuclear medicine department heads, and hospital procurement officers across 12 countries. All market size estimates and growth projections have been validated through triangulation across multiple independent data points, ensuring analytical reliability for strategic decision-making.

Radiopharmaceuticals are pharmaceutical formulations containing radioactive isotopes used in both diagnostic and therapeutic medical procedures. These products are supplied across regulated healthcare environments, including hospitals, diagnostic imaging centers, ambulatory surgical centers, and cancer research institutes. Their primary function is to support visualization of biological processes, functional imaging, and targeted radionuclide therapies.

The market includes a broad range of radioisotopes such as technetium-99m, fluorine-18, iodine-131, lutetium-177, gallium-68, yttrium-90, and others. Demand is shaped by factors including isotope accessibility, clinical suitability, imaging intensity, source production capabilities, and institutional adoption of nuclear medicine workflows.

Radiopharmaceuticals Market Size & Forecast:

  • 2026 Market Size: USD 7.82 billion
  • 2036 Projected Market Size: USD 13.78 billion
  • CAGR (2026-2036): 5.48%

Key Insights of the Radiopharmaceuticals Market Report:

  • Historical Analysis (2017 - 2024): Evaluates market evolution, demand patterns, and industry responses over time.
  • Forecast and Projections (2026 - 2036): Provides insights into future trends, technology adoption, and market expansion.
  • Growth Rate (CAGR): Highlights long-term growth potential and investment opportunities.

This report provides detailed Radiopharmaceuticals market size analysis, growth trends, competitive benchmarking, and future industry outlook.

Global Radiopharmaceuticals Market Size Growth Forecast 2036 Analysis
Request Radiopharmaceuticals Market Free PDF Sample

Key Growth Drivers

Increasing Prevalence of Cancer and Chronic Diseases

One of the primary drivers of the radiopharmaceuticals market is the growing burden of cancer worldwide. Oncology remains the largest application segment, accounting for 50.6% of total market demand in 2026 due to extensive use in cancer detection, staging, treatment monitoring, and radioligand therapies. The rising need for repeated molecular imaging and targeted therapeutic interventions continues to strengthen demand across global healthcare systems.

Expansion of Nuclear Medicine Infrastructure

The increasing establishment of cyclotrons, nuclear reactors, and radiopharmacy facilities is expanding the availability of critical isotopes. This infrastructure growth is improving access to diagnostic and therapeutic radiopharmaceuticals, particularly in emerging economies where healthcare modernization is accelerating.

Technological Advancements in Precision Medicine

Advances in theranostics, personalized medicine, and targeted radionuclide therapies are broadening the clinical applications of radiopharmaceuticals. New isotope development and next-generation tracers are creating opportunities for more precise disease management.

Market Segmentation Analysis

The radiopharmaceuticals market is segmented primarily by radioisotope type and clinical application, reflecting the diverse diagnostic and therapeutic roles these products serve across modern healthcare systems. Each segment contributes uniquely to market growth based on procedural volume, disease prevalence, isotope accessibility, and technological adoption.

By Radioisotope

Radioisotopes form the core of radiopharmaceutical functionality, with each isotope offering specific diagnostic or therapeutic advantages depending on clinical use. Among all radioisotopes, technetium-99m holds the dominant market position, accounting for 47.6% of global share in 2026, based on procedural volume analysis across SPECT imaging facilities in North America, Europe, and Asia Pacific conducted as part of this study. Its leadership is attributed to its widespread use in routine nuclear medicine procedures, favorable imaging characteristics, relatively short half-life, and compatibility with a broad range of diagnostic scans. Technetium-99m is extensively used in cardiac perfusion imaging, bone scans, renal diagnostics, thyroid evaluations, and neurological assessments, making it the foundational isotope in conventional SPECT imaging workflows. Its long-standing clinical familiarity and integration across hospital systems continue to reinforce its market leadership.

  • Fluorine-18 represents another highly significant isotope, particularly in PET imaging, where it is widely used in oncology, neurology, and cardiology. Its role in fluorodeoxyglucose (FDG) imaging has made it essential for cancer detection, metabolic analysis, and disease staging.
  • Iodine-131 remains an important therapeutic and diagnostic isotope, especially in thyroid-related disorders and selected oncology applications. It is commonly used for thyroid cancer treatment and hyperthyroidism management due to its targeted radioactive properties.
  • Lutetium-177 has gained increasing attention in precision oncology because of its use in targeted radionuclide therapies, including prostate cancer and neuroendocrine tumor treatment. As theranostics continues to expand, Lutetium-177 is expected to witness strong future demand.
  • Gallium-68 is emerging as a critical isotope in advanced PET imaging, particularly for neuroendocrine tumors and prostate-specific membrane antigen (PSMA)-based diagnostics. Its expanding use in precision medicine highlights its strategic growth potential.
  • Rubidium-82 is primarily used in myocardial perfusion imaging and has established relevance in cardiology due to its rapid diagnostic capability for coronary artery disease.

Collectively, these isotopes support both established nuclear imaging pathways and newer precision medicine strategies, creating a balanced market landscape between diagnostic continuity and therapeutic innovation.

By Application

Oncology leads the radiopharmaceuticals market with 50.6% share in 2026, driven by extensive use in cancer detection, staging, therapy planning, disease monitoring, and targeted radioligand treatments. Growing cancer prevalence and wider PET/SPECT adoption continue to reinforce its dominance through personalized and precision-based care.

  • Cardiology remains a key segment, supported by radiopharmaceutical use in myocardial perfusion imaging, coronary artery disease diagnosis, and cardiac function assessment amid rising cardiovascular cases.
  • Neurology is expanding steadily with increasing applications in diagnosing Alzheimers, Parkinsons, epilepsy, dementia, and cerebrovascular diseases through advanced brain imaging.
  • Gastroenterology and nephrology utilize radiopharmaceuticals for digestive system diagnostics, liver studies, renal perfusion, kidney function, and urinary tract evaluation.
  • Neuroendocrinology is an emerging segment, gaining importance through targeted imaging and therapies for neuroendocrine tumors, endocrine disorders, and hormonal assessments.
Global Radiopharmaceuticals Market Size Growth Forecast 2036 Analysis
Enquiry Before Buy Radiopharmaceuticals Market and Free PDF Sample

Regional Outlook

The global radiopharmaceuticals market shows distinct regional growth patterns driven by healthcare infrastructure maturity, isotope supply capabilities, regulatory frameworks, and disease burden.

North America

North America leads the global radiopharmaceuticals market, underpinned by mature nuclear medicine networks, high cancer prevalence, and strong institutional adoption of PET and SPECT technologies. The United States accounts for the largest share, driven by stable procedural volumes, robust regulatory oversight from the FDA and NRC, and established isotope supply relationships. Canada contributes through expanding clinical use and growing access to validated nuclear medicine procedures.

East Asia

East Asia is the fastest-growing regional market, with China projected to expand at a CAGR of 8.5% from 2026 to 2036 the highest among all major national markets. Growth is driven by large-scale healthcare infrastructure investment, expanding hospital-based imaging capacity, and rapid oncology care development. Japan and South Korea maintain strong positions due to advanced medical systems and deep technology integration.

South Asia & Pacific

South Asia & Pacific offers high long-term growth potential. India is forecast to grow at a CAGR of 5.9% through 2036, supported by rising cancer incidence, expanding oncology imaging infrastructure, and broader nuclear medicine access across both public and private healthcare systems. ASEAN nations are emerging contributors as radiopharmaceutical supply chains gradually expand across the region.

Europe

Western Europe is a mature, stable market anchored by stringent regulatory standards, protocol-driven healthcare systems, and consistent demand from oncology and neurology applications. Germany, France, the UK, and Italy are the primary revenue contributors. While growth rates are moderate relative to emerging markets, increasing investment in precision medicine and targeted radionuclide therapies supports long-term market resilience.

Overall, regional market performance reflects a dual dynamic within the global radiopharmaceuticals industry: developed markets such as North America and Western Europe continue to provide stability through established infrastructure and recurring demand, while emerging regions such as East Asia and South Asia & Pacific are driving higher growth through healthcare expansion and modernization. This balance between mature institutional markets and rapidly developing healthcare ecosystems is expected to shape the future trajectory of the global radiopharmaceuticals market through 2036.

Market Challenges

Despite the positive long-term outlook for the radiopharmaceuticals market, several structural and operational challenges continue to influence industry development. These barriers affect market scalability, supply continuity, and institutional adoption, making operational resilience a critical factor for sustained growth.

  • One of the most significant challenges is the limited availability of isotope production sources. Many radiopharmaceuticals depend on a relatively small number of nuclear reactors and cyclotrons for isotope generation, creating supply concentration risks.
  • Another major challenge is the short half-life of many radioisotopes, which creates substantial logistical complexity.
  • Regulatory compliance also represents a major barrier due to strict oversight related to radioactive material handling, manufacturing protocols, transportation standards, storage safety, and patient administration.
  • Transportation and storage demands further complicate market operations due to specialized containment and logistics requirements.
  • Infrastructure investment remains a considerable challenge, particularly in developing regions.

Competitive Landscape

The global radiopharmaceuticals market is moderately concentrated, with competition centered around operational reliability, isotope accessibility, regulatory expertise, and clinical relevance.

Major companies operating in the market include Siemens AG, Curium, Lantheus Holdings, Inc., Bayer AG, Eckert & Ziegler, and GE Healthcare.

  • Isotope Sourcing and Production Capacity Companies with secure access to reactors, cyclotrons, and isotope generation technologies hold significant advantages.
  • Regulatory Compliance and Quality Assurance Suppliers with strong compliance systems and validated manufacturing frameworks are better positioned to secure institutional trust.
  • Clinical Portfolio Diversification Broad portfolios across diagnostic and therapeutic isotopes strengthen integrated healthcare offerings.
  • Based on our primary research, Lantheus Holdings and Novartis have emerged as the most aggressively expanding players in the radioligand therapy segment as of early 2026, driven by pipeline approvals and strategic manufacturing investments. Curium and Cardinal Health continue to dominate conventional SPECT isotope distribution through established hospital network contracts.

Future Market Opportunities

  • Expansion of Radioligand Therapies Targeted treatment solutions for cancers such as prostate cancer and neuroendocrine tumors.
  • Growth of Theranostics Integrating diagnosis and therapy through paired radiopharmaceuticals.
  • Rising Use of Targeted Oncology Isotopes Increasing adoption of isotopes such as Lutetium-177 and Gallium-68.
  • Development of Novel PET Tracers Broadening applications beyond oncology into neurology, cardiology, and rare diseases.
  • Emerging Market Penetration Healthcare modernization in China, India, and ASEAN nations.

As healthcare systems increasingly prioritize early detection, molecular precision, and personalized treatment pathways, radiopharmaceuticals are expected to become even more integral to future healthcare delivery. The convergence of advanced diagnostics, targeted therapeutics, and global healthcare expansion positions the market for sustained strategic growth over the coming decade.

Global Radiopharmaceuticals Regional Market Size Growth Forecast 2036 Analysis
Request Customization Radiopharmaceuticals Market

Competitive Analysis and Company Profiles

This section analyzes how leading companies differentiate through isotope sourcing reliability, GMP-compliant manufacturing, regulatory expertise, clinical portfolio breadth, and speed of isotope delivery to healthcare institutions. helping stakeholders evaluate innovation, operational efficiency, and competitive market positioning.

The company profiles include business overview, product and service portfolios, financial performance, and geographic presence. The analysis also highlights recent developments such as partnerships, mergers, product launches, digital integration strategies, and regional expansion initiatives, helping stakeholders understand competitive intensity and benchmark leading industry participants.

Key Players Operating in the Radiopharmaceuticals Market Include:

  • Novartis
  • GE HealthCare
  • Cardinal Health
  • Curium Pharma
  • Bayer
  • Lantheus Holdings
  • Bracco Imaging
  • Jubilant Pharmova
  • Telix Pharmaceuticals
  • Eckert & Ziegler
  • Siemens Healthineers
  • PharmaLogic Holdings
  • NorthStar Medical Radioisotopes
  • ITM Isotope Technologies Munich
  • IBA Radiopharma Solutions

Report Scope

Quintile Reports has segmented the Radiopharmaceuticals market into the following segments:

Based on Product Type, the Radiopharmaceuticals market is segmented into:

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)

Based on Application / Indication, the Radiopharmaceuticals market is segmented into:

  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases

Based on End User, the Radiopharmaceuticals market is segmented into:

  • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
  • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
  • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
  • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
  • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
  • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)

Based on Technology, the Radiopharmaceuticals market is segmented into:

  • Positron Emission Tomography (PET/CT, PET/MRI)
  • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
  • Brachytherapy (Temporary Implant, Permanent Implant)
  • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
  • Beta Therapy (Systemic Beta Therapy, Radioembolization)
Report ScopeDetails
Report Version2026
Growth RateCAGR of 5.48 from 2026 to 2036
Base Year2025
Actual Estimates / Historical Data2017 - 2024
Forecast Period2026 - 2036
Quantitative UnitsRevenue in USD million/billion & CAGR from 2026 to 2036
Country ScopeNorth America (U.S., Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Sweden, Denmark, Norway, Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Colombia, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East & Africa).
The Segment Covered by Product Type
  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)
The Segment Covered by Application / Indication
  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases
Companies Covered
  • Novartis
  • GE HealthCare
  • Cardinal Health
  • Curium Pharma
  • Bayer
  • Lantheus Holdings
  • Bracco Imaging
  • Jubilant Pharmova
  • Telix Pharmaceuticals
  • Eckert & Ziegler
  • Siemens Healthineers
  • PharmaLogic Holdings
  • NorthStar Medical Radioisotopes
  • ITM Isotope Technologies Munich
  • IBA Radiopharma Solutions
Report CoverageRevenue forecast, company share, competitive landscape, growth factors, technology trends, and regional analysis
Free Customization Scope (Equivalent to 5 Analyst Working Days)If you require additional insights beyond the current scope, our analysts can customize the report to meet your specific business needs.

Why Trust This Radiopharmaceuticals Market Report

  • Comprehensive analysis based on validated industry data, expert interviews, and sector-specific insights
  • Coverage of global regulatory frameworks, environmental compliance standards, and operational safety benchmarks relevant to the industry
  • Detailed segmentation, competitive benchmarking, and strategic market intelligence across major global regions

Research Methodology

This report is based on a combination of primary and secondary research methodologies:

  • Primary Research: Interviews with nuclear medicine physicians, radiopharmacists, hospital procurement specialists, isotope manufacturers, and regulatory affairs experts.
  • Secondary Research: Data collected from company reports, industry publications, government databases, trade journals, and regulatory frameworks
  • Data Validation: Cross-verification using multiple industry sources, forecasting models, and analyst review processes to ensure accuracy and reliability
  • All findings are subject to internal editorial review before publication. Quintile Reports maintains a strict separation between research, analysis, and commercial functions to ensure objectivity.

Data Sources

  • Company annual reports and investor presentations
  • Industry associations, engineering publications, and sector-specific databases
  • Government trade, manufacturing, and regulatory databases
  • Internal market modeling and analyst estimates

Key Reasons to Purchase the Radiopharmaceuticals Market Research Report

  • Understand how expanding theranostics adoption, radioligand therapy approvals, and precision oncology trends are reshaping radiopharmaceutical demand.
  • Identify key growth drivers, constraints, and emerging opportunities influencing market expansion
  • Leverage advanced analytical tools to evaluate competitive intensity and supplier-buyer dynamics
  • Explore detailed market segmentation to uncover high-growth areas and investment opportunities
  • Understand regional performance trends and revenue contributions across major global markets
  • Benchmark leading market players and assess their strategic positioning
  • Stay informed about evolving market trends, technological advancements, and strategic developments
Global Radiopharmaceuticals Market Quintile Expertise
Request Discount on Radiopharmaceuticals Market

Available Customizations

Customization Options Offered by Quintile Reports

  • Request reports tailored to specific regions, countries, or global markets
  • Customize analysis based on specific product types, applications, deployment models, or industry segments
  • Include detailed profiling of additional competitors, emerging players, or niche technology providers

Radiopharmaceuticals Market Research Report

The Radiopharmaceuticals market report provides detailed insights into market size, share, and growth trends from 2026 to 2036, along with a comprehensive forecast outlook. The study combines historical analysis (20172024) with future projections to deliver a complete market perspective for stakeholders, investors, manufacturers, and strategic decision-makers. To request a sample PDF or obtain further information, contact our analyst team at sales@quintilereports.com.

Author: Shivani Singh, Senior Market Analyst Healthcare & Life Sciences
Last Updated: April 2026

Shivani Singh has over 8 years of experience in pharmaceutical and nuclear medicine market research, specializing in oncology diagnostics, radiopharmaceutical supply chains, and precision medicine trends. She leads the Healthcare & Life Sciences division at Quintile Reports, overseeing research across pharmaceuticals, biotechnology, nuclear medicine, and medical devices. The analysis draws on primary interviews conducted with nuclear medicine physicians, hospital procurement specialists, radiopharmacists, and isotope manufacturers across North America, Europe, and Asia Pacific during Q1 2026.

Reviewed By

Shivani Singh, Senior Lead Market Analyst Healthcare & Life Sciences Division, Quintile Reports. Shivani holds a postgraduate qualification in life sciences and has reviewed over 200 healthcare and pharmaceutical market reports.

List of Tables


Table 1 List of Abbreviation and acronyms
Table 2 List of Sources
Table 3 North America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 4 North America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 5 U.S. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 6 Canada Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 7 Europe Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 8 Europe Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 9 Germany Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 10 U.K. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 11 France Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 12 Italy Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 13 Spain Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 14 Sweden Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 15 Denmark Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 16 Norway Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 17 The Netherlands Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 18 Russia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 19 Asia Pacific Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 20 Asia Pacific Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 21 China Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 22 Japan Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 23 India Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 24 Australia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 25 South Korea Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 26 Thailand Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 27 Latin America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 28 Latin America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 29 Brazil Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 30 Mexico Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 31 Argentina Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 32 Middle East and Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 33 Middle East and Africa Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 34 South Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 35 Saudi Arabia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 36 UAE Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 37 Kuwait Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 38 Turkey Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035


List of Figures


Fig.1 Market research process
Fig.2 Market research approaches
Fig.3 Global Radiopharmaceuticals Market: market scenario
Fig.4 Global Radiopharmaceuticals Market competitive outlook
Fig.5 Global Radiopharmaceuticals Market driver analysis
Fig.6 Global Radiopharmaceuticals Market restraint analysis
Fig.7 Global Radiopharmaceuticals Market opportunity analysis
Fig.8 Global Radiopharmaceuticals Market trends analysis
Fig.9 Global Radiopharmaceuticals Market: Segment Analysis (Based on the scope)
Fig.10 Global Radiopharmaceuticals Market: regional analysis
Fig.11 Global market shares and leading market players
Fig.12 North America market share and leading players
Fig.13 Europe market share and leading players
Fig.14 Asia Pacific market share and leading players
Fig.15 Latin America market share and leading players
Fig.16 Middle East & Africa market share and leading players
Fig.17 North America, by country
Fig.18 North America
Fig.19 North America market estimates and forecast, 2017-2035
Fig.20 U.S.
Fig.21 Canada
Fig.22 Europe
Fig.23 Europe market estimates and forecast, 2017-2035
Fig.24 U.K.
Fig.25 Germany
Fig.26 France
Fig.27 Italy
Fig.28 Spain
Fig.29 Sweden
Fig.30 Denmark
Fig.31 Norway
Fig.32 The Netherlands
Fig.33 Russia
Fig.34 Asia Pacific
Fig.35 Asia Pacific market estimates and forecast, 2017-2035
Fig.36 China
Fig.37 Japan
Fig.38 India
Fig.39 Australia
Fig.40 South Korea
Fig.41 Thailand
Fig.42 Latin America
Fig.43 Latin America market estimates and forecast, 2017-2035
Fig.44 Brazil
Fig.45 Mexico
Fig.46 Argentina
Fig.47 Colombia
Fig.48 Middle East and Africa
Fig.49 Middle East and Africa market estimates and forecast, 2017-2035
Fig.50 Saudi Arabia
Fig.51 South Africa
Fig.52 UAE
Fig.53 Kuwait
Fig.54 Turkey

List of Tables


Table 1 List of Abbreviation and acronyms
Table 2 List of Sources
Table 3 North America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 4 North America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 5 U.S. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 6 Canada Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 7 Europe Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 8 Europe Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 9 Germany Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 10 U.K. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 11 France Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 12 Italy Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 13 Spain Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 14 Sweden Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 15 Denmark Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 16 Norway Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 17 The Netherlands Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 18 Russia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 19 Asia Pacific Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 20 Asia Pacific Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 21 China Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 22 Japan Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 23 India Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 24 Australia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 25 South Korea Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 26 Thailand Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 27 Latin America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 28 Latin America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 29 Brazil Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 30 Mexico Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 31 Argentina Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 32 Middle East and Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 33 Middle East and Africa Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 34 South Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 35 Saudi Arabia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 36 UAE Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 37 Kuwait Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 38 Turkey Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035


List of Figures


Fig.1 Market research process
Fig.2 Market research approaches
Fig.3 Global Radiopharmaceuticals Market: market scenario
Fig.4 Global Radiopharmaceuticals Market competitive outlook
Fig.5 Global Radiopharmaceuticals Market driver analysis
Fig.6 Global Radiopharmaceuticals Market restraint analysis
Fig.7 Global Radiopharmaceuticals Market opportunity analysis
Fig.8 Global Radiopharmaceuticals Market trends analysis
Fig.9 Global Radiopharmaceuticals Market: Segment Analysis (Based on the scope)
Fig.10 Global Radiopharmaceuticals Market: regional analysis
Fig.11 Global market shares and leading market players
Fig.12 North America market share and leading players
Fig.13 Europe market share and leading players
Fig.14 Asia Pacific market share and leading players
Fig.15 Latin America market share and leading players
Fig.16 Middle East & Africa market share and leading players
Fig.17 North America, by country
Fig.18 North America
Fig.19 North America market estimates and forecast, 2017-2035
Fig.20 U.S.
Fig.21 Canada
Fig.22 Europe
Fig.23 Europe market estimates and forecast, 2017-2035
Fig.24 U.K.
Fig.25 Germany
Fig.26 France
Fig.27 Italy
Fig.28 Spain
Fig.29 Sweden
Fig.30 Denmark
Fig.31 Norway
Fig.32 The Netherlands
Fig.33 Russia
Fig.34 Asia Pacific
Fig.35 Asia Pacific market estimates and forecast, 2017-2035
Fig.36 China
Fig.37 Japan
Fig.38 India
Fig.39 Australia
Fig.40 South Korea
Fig.41 Thailand
Fig.42 Latin America
Fig.43 Latin America market estimates and forecast, 2017-2035
Fig.44 Brazil
Fig.45 Mexico
Fig.46 Argentina
Fig.47 Colombia
Fig.48 Middle East and Africa
Fig.49 Middle East and Africa market estimates and forecast, 2017-2035
Fig.50 Saudi Arabia
Fig.51 South Africa
Fig.52 UAE
Fig.53 Kuwait
Fig.54 Turkey

Radiopharmaceuticals Market Segments

Radiopharmaceuticals Product Type Outlook (Revenue, USD Million, 2017 - 2035)

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)

Radiopharmaceuticals Application / Indication Outlook (Revenue, USD Million, 2017 - 2035)

  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases

Radiopharmaceuticals End User Outlook (Revenue, USD Million, 2017 - 2035)

  • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
  • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
  • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
  • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
  • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
  • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)

Radiopharmaceuticals Technology Outlook (Revenue, USD Million, 2017 - 2035)

  • Positron Emission Tomography (PET/CT, PET/MRI)
  • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
  • Brachytherapy (Temporary Implant, Permanent Implant)
  • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
  • Beta Therapy (Systemic Beta Therapy, Radioembolization)

Radiopharmaceuticals Regional Outlook (Revenue, USD Million, 2017 - 2035)

  • North America
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Europe
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Asia Pacific
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Latin America
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Middle East & Africa
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)

Report Content:

Qualitative Analysis

  • Industry overview
  • Research Objectives
  • Industry trends
  • Market drivers, Restraints and Opportunities
  • Market Size Estimate and Forecast
  • Growth Prospects
  • Porter's Analysis
  • PESTEL Analysis
  • Value Chain Analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Company Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecasts from 2017 - 2035
  • Market revenue estimates for Product Type up to 2035
  • Market revenue estimates for Application / Indication type up to 2035
  • Regional market size and forecast up to 2035
  • Country market size and forecast up to 2035
  • Company financials
  • Company Market Share Analysis

Radiopharmaceuticals Market Overview

The global radiopharmaceuticals market represents a critical segment of the healthcare and nuclear medicine industry, encompassing radioactive compounds used for diagnostic imaging and targeted therapeutic applications. These products are essential in modern clinical practice for disease detection, organ function assessment, treatment planning, and precision-based care, particularly in oncology, cardiology, neurology, and other specialized medical fields. Radiopharmaceuticals are commonly utilized in PET and SPECT imaging systems, enabling healthcare professionals to diagnose and monitor diseases with high clinical accuracy.

In 2026, the global radiopharmaceuticals market is valued at approximately USD 7.82 billion and is projected to reach USD 13.78 billion by 2036, registering a compound annual growth rate (CAGR) of 5.48% over the forecast period. These estimates are based on Quintile Reports primary research, cross-validated against data from industry associations, nuclear medicine institutional databases, and publicly available manufacturer disclosures.

Unlike aggregated secondary compilations, this report incorporates direct primary research conducted with radiopharmaceutical manufacturers, nuclear medicine department heads, and hospital procurement officers across 12 countries. All market size estimates and growth projections have been validated through triangulation across multiple independent data points, ensuring analytical reliability for strategic decision-making.

Radiopharmaceuticals are pharmaceutical formulations containing radioactive isotopes used in both diagnostic and therapeutic medical procedures. These products are supplied across regulated healthcare environments, including hospitals, diagnostic imaging centers, ambulatory surgical centers, and cancer research institutes. Their primary function is to support visualization of biological processes, functional imaging, and targeted radionuclide therapies.

The market includes a broad range of radioisotopes such as technetium-99m, fluorine-18, iodine-131, lutetium-177, gallium-68, yttrium-90, and others. Demand is shaped by factors including isotope accessibility, clinical suitability, imaging intensity, source production capabilities, and institutional adoption of nuclear medicine workflows.

Radiopharmaceuticals Market Size & Forecast:

  • 2026 Market Size: USD 7.82 billion
  • 2036 Projected Market Size: USD 13.78 billion
  • CAGR (2026-2036): 5.48%

Key Insights of the Radiopharmaceuticals Market Report:

  • Historical Analysis (2017 - 2024): Evaluates market evolution, demand patterns, and industry responses over time.
  • Forecast and Projections (2026 - 2036): Provides insights into future trends, technology adoption, and market expansion.
  • Growth Rate (CAGR): Highlights long-term growth potential and investment opportunities.

This report provides detailed Radiopharmaceuticals market size analysis, growth trends, competitive benchmarking, and future industry outlook.

Global Radiopharmaceuticals Market Size Growth Forecast 2036 Analysis
Request Radiopharmaceuticals Market Free PDF Sample

Key Growth Drivers

Increasing Prevalence of Cancer and Chronic Diseases

One of the primary drivers of the radiopharmaceuticals market is the growing burden of cancer worldwide. Oncology remains the largest application segment, accounting for 50.6% of total market demand in 2026 due to extensive use in cancer detection, staging, treatment monitoring, and radioligand therapies. The rising need for repeated molecular imaging and targeted therapeutic interventions continues to strengthen demand across global healthcare systems.

Expansion of Nuclear Medicine Infrastructure

The increasing establishment of cyclotrons, nuclear reactors, and radiopharmacy facilities is expanding the availability of critical isotopes. This infrastructure growth is improving access to diagnostic and therapeutic radiopharmaceuticals, particularly in emerging economies where healthcare modernization is accelerating.

Technological Advancements in Precision Medicine

Advances in theranostics, personalized medicine, and targeted radionuclide therapies are broadening the clinical applications of radiopharmaceuticals. New isotope development and next-generation tracers are creating opportunities for more precise disease management.

Market Segmentation Analysis

The radiopharmaceuticals market is segmented primarily by radioisotope type and clinical application, reflecting the diverse diagnostic and therapeutic roles these products serve across modern healthcare systems. Each segment contributes uniquely to market growth based on procedural volume, disease prevalence, isotope accessibility, and technological adoption.

By Radioisotope

Radioisotopes form the core of radiopharmaceutical functionality, with each isotope offering specific diagnostic or therapeutic advantages depending on clinical use. Among all radioisotopes, technetium-99m holds the dominant market position, accounting for 47.6% of global share in 2026, based on procedural volume analysis across SPECT imaging facilities in North America, Europe, and Asia Pacific conducted as part of this study. Its leadership is attributed to its widespread use in routine nuclear medicine procedures, favorable imaging characteristics, relatively short half-life, and compatibility with a broad range of diagnostic scans. Technetium-99m is extensively used in cardiac perfusion imaging, bone scans, renal diagnostics, thyroid evaluations, and neurological assessments, making it the foundational isotope in conventional SPECT imaging workflows. Its long-standing clinical familiarity and integration across hospital systems continue to reinforce its market leadership.

  • Fluorine-18 represents another highly significant isotope, particularly in PET imaging, where it is widely used in oncology, neurology, and cardiology. Its role in fluorodeoxyglucose (FDG) imaging has made it essential for cancer detection, metabolic analysis, and disease staging.
  • Iodine-131 remains an important therapeutic and diagnostic isotope, especially in thyroid-related disorders and selected oncology applications. It is commonly used for thyroid cancer treatment and hyperthyroidism management due to its targeted radioactive properties.
  • Lutetium-177 has gained increasing attention in precision oncology because of its use in targeted radionuclide therapies, including prostate cancer and neuroendocrine tumor treatment. As theranostics continues to expand, Lutetium-177 is expected to witness strong future demand.
  • Gallium-68 is emerging as a critical isotope in advanced PET imaging, particularly for neuroendocrine tumors and prostate-specific membrane antigen (PSMA)-based diagnostics. Its expanding use in precision medicine highlights its strategic growth potential.
  • Rubidium-82 is primarily used in myocardial perfusion imaging and has established relevance in cardiology due to its rapid diagnostic capability for coronary artery disease.

Collectively, these isotopes support both established nuclear imaging pathways and newer precision medicine strategies, creating a balanced market landscape between diagnostic continuity and therapeutic innovation.

By Application

Oncology leads the radiopharmaceuticals market with 50.6% share in 2026, driven by extensive use in cancer detection, staging, therapy planning, disease monitoring, and targeted radioligand treatments. Growing cancer prevalence and wider PET/SPECT adoption continue to reinforce its dominance through personalized and precision-based care.

  • Cardiology remains a key segment, supported by radiopharmaceutical use in myocardial perfusion imaging, coronary artery disease diagnosis, and cardiac function assessment amid rising cardiovascular cases.
  • Neurology is expanding steadily with increasing applications in diagnosing Alzheimers, Parkinsons, epilepsy, dementia, and cerebrovascular diseases through advanced brain imaging.
  • Gastroenterology and nephrology utilize radiopharmaceuticals for digestive system diagnostics, liver studies, renal perfusion, kidney function, and urinary tract evaluation.
  • Neuroendocrinology is an emerging segment, gaining importance through targeted imaging and therapies for neuroendocrine tumors, endocrine disorders, and hormonal assessments.
Global Radiopharmaceuticals Market Size Growth Forecast 2036 Analysis
Enquiry Before Buy Radiopharmaceuticals Market and Free PDF Sample

Regional Outlook

The global radiopharmaceuticals market shows distinct regional growth patterns driven by healthcare infrastructure maturity, isotope supply capabilities, regulatory frameworks, and disease burden.

North America

North America leads the global radiopharmaceuticals market, underpinned by mature nuclear medicine networks, high cancer prevalence, and strong institutional adoption of PET and SPECT technologies. The United States accounts for the largest share, driven by stable procedural volumes, robust regulatory oversight from the FDA and NRC, and established isotope supply relationships. Canada contributes through expanding clinical use and growing access to validated nuclear medicine procedures.

East Asia

East Asia is the fastest-growing regional market, with China projected to expand at a CAGR of 8.5% from 2026 to 2036 the highest among all major national markets. Growth is driven by large-scale healthcare infrastructure investment, expanding hospital-based imaging capacity, and rapid oncology care development. Japan and South Korea maintain strong positions due to advanced medical systems and deep technology integration.

South Asia & Pacific

South Asia & Pacific offers high long-term growth potential. India is forecast to grow at a CAGR of 5.9% through 2036, supported by rising cancer incidence, expanding oncology imaging infrastructure, and broader nuclear medicine access across both public and private healthcare systems. ASEAN nations are emerging contributors as radiopharmaceutical supply chains gradually expand across the region.

Europe

Western Europe is a mature, stable market anchored by stringent regulatory standards, protocol-driven healthcare systems, and consistent demand from oncology and neurology applications. Germany, France, the UK, and Italy are the primary revenue contributors. While growth rates are moderate relative to emerging markets, increasing investment in precision medicine and targeted radionuclide therapies supports long-term market resilience.

Overall, regional market performance reflects a dual dynamic within the global radiopharmaceuticals industry: developed markets such as North America and Western Europe continue to provide stability through established infrastructure and recurring demand, while emerging regions such as East Asia and South Asia & Pacific are driving higher growth through healthcare expansion and modernization. This balance between mature institutional markets and rapidly developing healthcare ecosystems is expected to shape the future trajectory of the global radiopharmaceuticals market through 2036.

Market Challenges

Despite the positive long-term outlook for the radiopharmaceuticals market, several structural and operational challenges continue to influence industry development. These barriers affect market scalability, supply continuity, and institutional adoption, making operational resilience a critical factor for sustained growth.

  • One of the most significant challenges is the limited availability of isotope production sources. Many radiopharmaceuticals depend on a relatively small number of nuclear reactors and cyclotrons for isotope generation, creating supply concentration risks.
  • Another major challenge is the short half-life of many radioisotopes, which creates substantial logistical complexity.
  • Regulatory compliance also represents a major barrier due to strict oversight related to radioactive material handling, manufacturing protocols, transportation standards, storage safety, and patient administration.
  • Transportation and storage demands further complicate market operations due to specialized containment and logistics requirements.
  • Infrastructure investment remains a considerable challenge, particularly in developing regions.

Competitive Landscape

The global radiopharmaceuticals market is moderately concentrated, with competition centered around operational reliability, isotope accessibility, regulatory expertise, and clinical relevance.

Major companies operating in the market include Siemens AG, Curium, Lantheus Holdings, Inc., Bayer AG, Eckert & Ziegler, and GE Healthcare.

  • Isotope Sourcing and Production Capacity Companies with secure access to reactors, cyclotrons, and isotope generation technologies hold significant advantages.
  • Regulatory Compliance and Quality Assurance Suppliers with strong compliance systems and validated manufacturing frameworks are better positioned to secure institutional trust.
  • Clinical Portfolio Diversification Broad portfolios across diagnostic and therapeutic isotopes strengthen integrated healthcare offerings.
  • Based on our primary research, Lantheus Holdings and Novartis have emerged as the most aggressively expanding players in the radioligand therapy segment as of early 2026, driven by pipeline approvals and strategic manufacturing investments. Curium and Cardinal Health continue to dominate conventional SPECT isotope distribution through established hospital network contracts.

Future Market Opportunities

  • Expansion of Radioligand Therapies Targeted treatment solutions for cancers such as prostate cancer and neuroendocrine tumors.
  • Growth of Theranostics Integrating diagnosis and therapy through paired radiopharmaceuticals.
  • Rising Use of Targeted Oncology Isotopes Increasing adoption of isotopes such as Lutetium-177 and Gallium-68.
  • Development of Novel PET Tracers Broadening applications beyond oncology into neurology, cardiology, and rare diseases.
  • Emerging Market Penetration Healthcare modernization in China, India, and ASEAN nations.

As healthcare systems increasingly prioritize early detection, molecular precision, and personalized treatment pathways, radiopharmaceuticals are expected to become even more integral to future healthcare delivery. The convergence of advanced diagnostics, targeted therapeutics, and global healthcare expansion positions the market for sustained strategic growth over the coming decade.

Global Radiopharmaceuticals Regional Market Size Growth Forecast 2036 Analysis
Request Customization Radiopharmaceuticals Market

Competitive Analysis and Company Profiles

This section analyzes how leading companies differentiate through isotope sourcing reliability, GMP-compliant manufacturing, regulatory expertise, clinical portfolio breadth, and speed of isotope delivery to healthcare institutions. helping stakeholders evaluate innovation, operational efficiency, and competitive market positioning.

The company profiles include business overview, product and service portfolios, financial performance, and geographic presence. The analysis also highlights recent developments such as partnerships, mergers, product launches, digital integration strategies, and regional expansion initiatives, helping stakeholders understand competitive intensity and benchmark leading industry participants.

Key Players Operating in the Radiopharmaceuticals Market Include:

  • Novartis
  • GE HealthCare
  • Cardinal Health
  • Curium Pharma
  • Bayer
  • Lantheus Holdings
  • Bracco Imaging
  • Jubilant Pharmova
  • Telix Pharmaceuticals
  • Eckert & Ziegler
  • Siemens Healthineers
  • PharmaLogic Holdings
  • NorthStar Medical Radioisotopes
  • ITM Isotope Technologies Munich
  • IBA Radiopharma Solutions

Report Scope

Quintile Reports has segmented the Radiopharmaceuticals market into the following segments:

Based on Product Type, the Radiopharmaceuticals market is segmented into:

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)

Based on Application / Indication, the Radiopharmaceuticals market is segmented into:

  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases

Based on End User, the Radiopharmaceuticals market is segmented into:

  • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
  • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
  • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
  • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
  • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
  • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)

Based on Technology, the Radiopharmaceuticals market is segmented into:

  • Positron Emission Tomography (PET/CT, PET/MRI)
  • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
  • Brachytherapy (Temporary Implant, Permanent Implant)
  • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
  • Beta Therapy (Systemic Beta Therapy, Radioembolization)
Report ScopeDetails
Report Version2026
Growth RateCAGR of 5.48 from 2026 to 2036
Base Year2025
Actual Estimates / Historical Data2017 - 2024
Forecast Period2026 - 2036
Quantitative UnitsRevenue in USD million/billion & CAGR from 2026 to 2036
Country ScopeNorth America (U.S., Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Sweden, Denmark, Norway, Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Colombia, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East & Africa).
The Segment Covered by Product Type
  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)
The Segment Covered by Application / Indication
  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases
Companies Covered
  • Novartis
  • GE HealthCare
  • Cardinal Health
  • Curium Pharma
  • Bayer
  • Lantheus Holdings
  • Bracco Imaging
  • Jubilant Pharmova
  • Telix Pharmaceuticals
  • Eckert & Ziegler
  • Siemens Healthineers
  • PharmaLogic Holdings
  • NorthStar Medical Radioisotopes
  • ITM Isotope Technologies Munich
  • IBA Radiopharma Solutions
Report CoverageRevenue forecast, company share, competitive landscape, growth factors, technology trends, and regional analysis
Free Customization Scope (Equivalent to 5 Analyst Working Days)If you require additional insights beyond the current scope, our analysts can customize the report to meet your specific business needs.

Why Trust This Radiopharmaceuticals Market Report

  • Comprehensive analysis based on validated industry data, expert interviews, and sector-specific insights
  • Coverage of global regulatory frameworks, environmental compliance standards, and operational safety benchmarks relevant to the industry
  • Detailed segmentation, competitive benchmarking, and strategic market intelligence across major global regions

Research Methodology

This report is based on a combination of primary and secondary research methodologies:

  • Primary Research: Interviews with nuclear medicine physicians, radiopharmacists, hospital procurement specialists, isotope manufacturers, and regulatory affairs experts.
  • Secondary Research: Data collected from company reports, industry publications, government databases, trade journals, and regulatory frameworks
  • Data Validation: Cross-verification using multiple industry sources, forecasting models, and analyst review processes to ensure accuracy and reliability
  • All findings are subject to internal editorial review before publication. Quintile Reports maintains a strict separation between research, analysis, and commercial functions to ensure objectivity.

Data Sources

  • Company annual reports and investor presentations
  • Industry associations, engineering publications, and sector-specific databases
  • Government trade, manufacturing, and regulatory databases
  • Internal market modeling and analyst estimates

Key Reasons to Purchase the Radiopharmaceuticals Market Research Report

  • Understand how expanding theranostics adoption, radioligand therapy approvals, and precision oncology trends are reshaping radiopharmaceutical demand.
  • Identify key growth drivers, constraints, and emerging opportunities influencing market expansion
  • Leverage advanced analytical tools to evaluate competitive intensity and supplier-buyer dynamics
  • Explore detailed market segmentation to uncover high-growth areas and investment opportunities
  • Understand regional performance trends and revenue contributions across major global markets
  • Benchmark leading market players and assess their strategic positioning
  • Stay informed about evolving market trends, technological advancements, and strategic developments
Global Radiopharmaceuticals Market Quintile Expertise
Request Discount on Radiopharmaceuticals Market

Available Customizations

Customization Options Offered by Quintile Reports

  • Request reports tailored to specific regions, countries, or global markets
  • Customize analysis based on specific product types, applications, deployment models, or industry segments
  • Include detailed profiling of additional competitors, emerging players, or niche technology providers

Radiopharmaceuticals Market Research Report

The Radiopharmaceuticals market report provides detailed insights into market size, share, and growth trends from 2026 to 2036, along with a comprehensive forecast outlook. The study combines historical analysis (20172024) with future projections to deliver a complete market perspective for stakeholders, investors, manufacturers, and strategic decision-makers. To request a sample PDF or obtain further information, contact our analyst team at sales@quintilereports.com.

Author: Shivani Singh, Senior Market Analyst Healthcare & Life Sciences
Last Updated: April 2026

Shivani Singh has over 8 years of experience in pharmaceutical and nuclear medicine market research, specializing in oncology diagnostics, radiopharmaceutical supply chains, and precision medicine trends. She leads the Healthcare & Life Sciences division at Quintile Reports, overseeing research across pharmaceuticals, biotechnology, nuclear medicine, and medical devices. The analysis draws on primary interviews conducted with nuclear medicine physicians, hospital procurement specialists, radiopharmacists, and isotope manufacturers across North America, Europe, and Asia Pacific during Q1 2026.

Reviewed By

Shivani Singh, Senior Lead Market Analyst Healthcare & Life Sciences Division, Quintile Reports. Shivani holds a postgraduate qualification in life sciences and has reviewed over 200 healthcare and pharmaceutical market reports.

List of Tables


Table 1 List of Abbreviation and acronyms
Table 2 List of Sources
Table 3 North America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 4 North America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 5 U.S. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 6 Canada Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 7 Europe Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 8 Europe Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 9 Germany Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 10 U.K. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 11 France Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 12 Italy Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 13 Spain Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 14 Sweden Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 15 Denmark Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 16 Norway Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 17 The Netherlands Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 18 Russia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 19 Asia Pacific Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 20 Asia Pacific Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 21 China Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 22 Japan Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 23 India Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 24 Australia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 25 South Korea Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 26 Thailand Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 27 Latin America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 28 Latin America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 29 Brazil Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 30 Mexico Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 31 Argentina Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 32 Middle East and Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 33 Middle East and Africa Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 34 South Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 35 Saudi Arabia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 36 UAE Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 37 Kuwait Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 38 Turkey Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035


List of Figures


Fig.1 Market research process
Fig.2 Market research approaches
Fig.3 Global Radiopharmaceuticals Market: market scenario
Fig.4 Global Radiopharmaceuticals Market competitive outlook
Fig.5 Global Radiopharmaceuticals Market driver analysis
Fig.6 Global Radiopharmaceuticals Market restraint analysis
Fig.7 Global Radiopharmaceuticals Market opportunity analysis
Fig.8 Global Radiopharmaceuticals Market trends analysis
Fig.9 Global Radiopharmaceuticals Market: Segment Analysis (Based on the scope)
Fig.10 Global Radiopharmaceuticals Market: regional analysis
Fig.11 Global market shares and leading market players
Fig.12 North America market share and leading players
Fig.13 Europe market share and leading players
Fig.14 Asia Pacific market share and leading players
Fig.15 Latin America market share and leading players
Fig.16 Middle East & Africa market share and leading players
Fig.17 North America, by country
Fig.18 North America
Fig.19 North America market estimates and forecast, 2017-2035
Fig.20 U.S.
Fig.21 Canada
Fig.22 Europe
Fig.23 Europe market estimates and forecast, 2017-2035
Fig.24 U.K.
Fig.25 Germany
Fig.26 France
Fig.27 Italy
Fig.28 Spain
Fig.29 Sweden
Fig.30 Denmark
Fig.31 Norway
Fig.32 The Netherlands
Fig.33 Russia
Fig.34 Asia Pacific
Fig.35 Asia Pacific market estimates and forecast, 2017-2035
Fig.36 China
Fig.37 Japan
Fig.38 India
Fig.39 Australia
Fig.40 South Korea
Fig.41 Thailand
Fig.42 Latin America
Fig.43 Latin America market estimates and forecast, 2017-2035
Fig.44 Brazil
Fig.45 Mexico
Fig.46 Argentina
Fig.47 Colombia
Fig.48 Middle East and Africa
Fig.49 Middle East and Africa market estimates and forecast, 2017-2035
Fig.50 Saudi Arabia
Fig.51 South Africa
Fig.52 UAE
Fig.53 Kuwait
Fig.54 Turkey

Radiopharmaceuticals Market Segments

Radiopharmaceuticals Product Type Outlook (Revenue, USD Million, 2017 - 2035)

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
  • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
  • Therapeutic Radiopharmaceuticals
  • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
  • Alpha Emitters (Radium-223, Actinium-225)
  • Brachytherapy Isotopes (Cesium-131, Iridium-192)

Radiopharmaceuticals Application / Indication Outlook (Revenue, USD Million, 2017 - 2035)

  • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
  • Cardiology
  • Neurology
  • Gastroenterology
  • Nephrology
  • Endocrinology
  • Pulmonology / Respiratory
  • Musculoskeletal Disorders
  • Other Chronic Diseases

Radiopharmaceuticals End User Outlook (Revenue, USD Million, 2017 - 2035)

  • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
  • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
  • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
  • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
  • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
  • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)

Radiopharmaceuticals Technology Outlook (Revenue, USD Million, 2017 - 2035)

  • Positron Emission Tomography (PET/CT, PET/MRI)
  • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
  • Brachytherapy (Temporary Implant, Permanent Implant)
  • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
  • Beta Therapy (Systemic Beta Therapy, Radioembolization)

Radiopharmaceuticals Regional Outlook (Revenue, USD Million, 2017 - 2035)

  • North America
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Europe
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Asia Pacific
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Latin America
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)
  • Middle East & Africa
    • Radiopharmaceuticals Market, By Product Type Outlook
      • Diagnostic Radiopharmaceuticals
      • PET Radiopharmaceuticals (Fluorine-18 (F-18), Gallium-68 (Ga-68), Rubidium-82 (Rb-82), Carbon-11 (C-11))
      • SPECT Radiopharmaceuticals (Technetium-99m (Tc-99m), Iodine-123 (I-123), Thallium-201 (Tl-201), Xenon-133)
      • Therapeutic Radiopharmaceuticals
      • Beta Emitters (Iodine-131 (I-131), Lutetium-177 (Lu-177), Yttrium-90 (Y-90), Samarium-153)
      • Alpha Emitters (Radium-223, Actinium-225)
      • Brachytherapy Isotopes (Cesium-131, Iridium-192)
    • Radiopharmaceuticals Market, By Application / Indication Outlook
      • Oncology (Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Bone Metastasis)
      • Cardiology
      • Neurology
      • Gastroenterology
      • Nephrology
      • Endocrinology
      • Pulmonology / Respiratory
      • Musculoskeletal Disorders
      • Other Chronic Diseases
    • Radiopharmaceuticals Market, By End User Outlook
      • Hospitals & Clinics (Public Hospitals, Private Hospitals, Multispecialty Clinics)
      • Diagnostic Imaging Centers (PET Centers, SPECT Centers, Independent Imaging Labs)
      • Ambulatory Surgical Centers (Cancer Day Care Centers, Outpatient Procedure Units)
      • Academic & Research Institutes (University Hospitals, Nuclear Medicine Research Labs)
      • Cancer Research Centers (Oncology Institutes, Specialty Cancer Hospitals)
      • Specialty Nuclear Medicine Centers (Radiotheranostics Centers, Isotope Therapy Centers)
    • Radiopharmaceuticals Market, By Technology Outlook
      • Positron Emission Tomography (PET/CT, PET/MRI)
      • Single Photon Emission Computed Tomography (SPECT/CT, Conventional SPECT)
      • Brachytherapy (Temporary Implant, Permanent Implant)
      • Alpha Therapy (Targeted Alpha Therapy, Bone-Targeted Alpha Therapy)
      • Beta Therapy (Systemic Beta Therapy, Radioembolization)

Report Content:

Qualitative Analysis

  • Industry overview
  • Research Objectives
  • Industry trends
  • Market drivers, Restraints and Opportunities
  • Market Size Estimate and Forecast
  • Growth Prospects
  • Porter's Analysis
  • PESTEL Analysis
  • Value Chain Analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Company Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecasts from 2017 - 2035
  • Market revenue estimates for Product Type up to 2035
  • Market revenue estimates for Application / Indication type up to 2035
  • Regional market size and forecast up to 2035
  • Country market size and forecast up to 2035
  • Company financials
  • Company Market Share Analysis
List of Tables


Table 1 List of Abbreviation and acronyms
Table 2 List of Sources
Table 3 North America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 4 North America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 5 U.S. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 6 Canada Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 7 Europe Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 8 Europe Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 9 Germany Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 10 U.K. Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 11 France Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 12 Italy Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 13 Spain Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 14 Sweden Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 15 Denmark Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 16 Norway Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 17 The Netherlands Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 18 Russia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 19 Asia Pacific Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 20 Asia Pacific Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 21 China Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 22 Japan Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 23 India Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 24 Australia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 25 South Korea Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 26 Thailand Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 27 Latin America Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 28 Latin America Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 29 Brazil Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 30 Mexico Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 31 Argentina Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 32 Middle East and Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 33 Middle East and Africa Global Radiopharmaceuticals Market, by Region, (USD Million) 2017-2035
Table 34 South Africa Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 35 Saudi Arabia Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 36 UAE Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 37 Kuwait Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035
Table 38 Turkey Global Radiopharmaceuticals Market, by Segment Analysis, (USD Million) 2017-2035


List of Figures


Fig.1 Market research process
Fig.2 Market research approaches
Fig.3 Global Radiopharmaceuticals Market: market scenario
Fig.4 Global Radiopharmaceuticals Market competitive outlook
Fig.5 Global Radiopharmaceuticals Market driver analysis
Fig.6 Global Radiopharmaceuticals Market restraint analysis
Fig.7 Global Radiopharmaceuticals Market opportunity analysis
Fig.8 Global Radiopharmaceuticals Market trends analysis
Fig.9 Global Radiopharmaceuticals Market: Segment Analysis (Based on the scope)
Fig.10 Global Radiopharmaceuticals Market: regional analysis
Fig.11 Global market shares and leading market players
Fig.12 North America market share and leading players
Fig.13 Europe market share and leading players
Fig.14 Asia Pacific market share and leading players
Fig.15 Latin America market share and leading players
Fig.16 Middle East & Africa market share and leading players
Fig.17 North America, by country
Fig.18 North America
Fig.19 North America market estimates and forecast, 2017-2035
Fig.20 U.S.
Fig.21 Canada
Fig.22 Europe
Fig.23 Europe market estimates and forecast, 2017-2035
Fig.24 U.K.
Fig.25 Germany
Fig.26 France
Fig.27 Italy
Fig.28 Spain
Fig.29 Sweden
Fig.30 Denmark
Fig.31 Norway
Fig.32 The Netherlands
Fig.33 Russia
Fig.34 Asia Pacific
Fig.35 Asia Pacific market estimates and forecast, 2017-2035
Fig.36 China
Fig.37 Japan
Fig.38 India
Fig.39 Australia
Fig.40 South Korea
Fig.41 Thailand
Fig.42 Latin America
Fig.43 Latin America market estimates and forecast, 2017-2035
Fig.44 Brazil
Fig.45 Mexico
Fig.46 Argentina
Fig.47 Colombia
Fig.48 Middle East and Africa
Fig.49 Middle East and Africa market estimates and forecast, 2017-2035
Fig.50 Saudi Arabia
Fig.51 South Africa
Fig.52 UAE
Fig.53 Kuwait
Fig.54 Turkey

Choose License Type

Secure Payment


img1
Frequently Asked Questions ?
  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Immediate / Within 24-48 hours - Working days

  • Online Payments with PayPal and CCavenue

  • You can order a report by picking any of the payment methods which is bank wire or online payment through any Debit/Credit card or PayPal.

  • Email

  • Hard Copy

Related Reports

Dioxin Analyzer Market

Report Overview: The Global Dioxin Analyzer Market was valued at USD 317.19 million in 2025 and is p

Read More

Face Shield Market

Report Descriptions: The Global Face Shield Market was valued at $3.0294 billion in 2024 and is proj

Read More

Healthcare Fabrics Market

Report Descriptions: The Global Healthcare Fabrics Market was estimated at $13.821 billion in 2023 a

Read More


Request Sample   
Buy Now